Cesca Therapeutics (KOOL) Narrows Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Cesca Therapeutics Reports First Quarter Fiscal 2015 Results
November 13, 2014 4:00 PM ESTCompany Completes Its Pivotal Clinical Trial Protocol for Treating Patients With Critical Limb Ischemia for Submission to the FDA
Management Will Hold a Conference Call Today at 2:00pm Pacific (5:00pm Eastern) to Review the First Quarter Fiscal 2015 Financial Results
RANCHO CORDOVA, Calif., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the first quarter of fiscal 2015 and reported on the progress of its clinical programs.
"We have made important progress advancing our clinical... More
